Alira Health

Alira Health

2023 Biologics and Advanced Therapies Contract Manufacturing Report is Launched

The comprehensive study reveals the key drivers of robust innovation, growth, and investment in the evolving market

Published on:
July 10, 2023

FRAMINGHAM, Mass. – July 10, 2023 – Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announced today the publication of the 2023 Biologics and Advanced Therapies Contract Manufacturing Report. The study explores the rapidly growing global Biologics and Advanced Therapies (ATs) market, with a focus on North America, Europe, and the Asia-Pacific region, including an in-depth market analysis, detailed examination of transactional activity, insight on the development of Biologics and ATs CDMO services, and market outlook.

The Biologics and ATs CDMO market, which has proven to be a primary driver of innovation and blockbuster drug development within the pharmaceutical industry, is projected to continue experiencing significant growth, rising from $18.6 billion in 2022 to $36.0 billion in 2027, at a Compound Annual Growth Rate (CAGR) of 14.1%.

To accompany the strong markets in North America and Europe, the Asia-Pacific region is expected to factor significantly in future growth, leveraging innovation in biosimilars, favorable government policies, and the expected widespread adoption of biologic therapies. Within these regions, the market continues to be concentrated with large and medium-sized CDMOs comprising 90% of revenue, while micro manufacturers generate only about 10% despite representing the majority of players.

As such, the smaller organizations provide a wide array of merger and acquisition opportunities, and M&A activities in the biologics CDMO sector saw a surge in 2021 and 2022 compared to previous years.

To support the strong market growth and demand for an end-to-end approach, CDMOs are horizontally integrating their services to provide manufacturing and analytical services at various stages, vertically integrating to cater to diverse customer needs throughout the product lifecycle, and venturing into new domains of biologics manufacturing, such as viral vectors and plasmid manufacturing. These integration strategies lessen the time and risks involved in successful API production while effectively managing supply chain and cold chain logistics. The expanding capabilities position the pharmaceutical CDMO market in a solid position to support the projected growth of the biologic pharmaceutical market over the next five years.




About Alira Health

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence. Alira Health’s integrated and multidisciplinary team of over 800 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.

2023 biologics and ats report cover

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.